Biogen Inc (BIIB)

$194.38 +11.00 (6.00%)
Market Cap 26.91B
Revenue (ttm) 9.89B
Net Income (ttm) 1.29B
EPS (ttm) N/A
PE Ratio 11.82
Forward PE 11.46
Profit Margin 13.07%
Debt to Equity Ratio 0.34
Volume 2,453,700
Avg Vol 1,133,264
Day's Range N/A - N/A
Shares Out 146.76M
Stochastic %K 93%
Beta 0.16
Analysts Sell
Price Target $213.14

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referenc...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 617 679 2000
Address:
225 Binney Street, Cambridge, United States
VolumeTactician
VolumeTactician Apr. 30 at 5:38 AM
$LEU $CAG $BIIB $BETA $AVPT Nuclear fuel/uranium theme, consumer staples stability, biotech pipelines, speculative tokens, and Microsoft-adjacent SaaS (AVPT) balance defense with growth.
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 30 at 3:55 AM
$BIIB Share Price: $194.59 Contract Selected: May 22, 2026 $195 Calls Buy Zone: $4.50 – $5.57 Target Zone: $8.02 – $9.80 Potential Upside: 68% ROI Time to Expiration: 22 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
RunnerSignals
RunnerSignals Apr. 29 at 8:10 PM
market warriors $TENB $HUM $CHGG $BIIB $SYRE reversed from red to strong green closes with 6–12% intraday swings and volume 1.2x–1.6x avg
0 · Reply
EarningsLens_ai
EarningsLens_ai Apr. 29 at 1:22 PM
$BIIB blew past estimates but the story underneath is more complicated. Cash flow nearly tripled, which sounds great until you see cost of revenue growing 3x faster than revenue and debt up 38% YoY to $6.29B. Q2 working capital reversal is the thing to watch.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Apr. 29 at 10:16 AM
$BIIB Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $2.17 up 31.52% YoY • Reported revenue of $2.48B up 1.93% YoY • Biogen updated full year 2026 Non-GAAP diluted EPS guidance to $14.25 to $15.25, reflecting an approximately $1.00 impact from acquired IPR&D charges, and expects total revenue to decline by a mid-single digit percentage.
0 · Reply
trichomy
trichomy Apr. 27 at 2:39 PM
$INMB $LEMB $BIIB Let's go InmuneBio!! https://claude.ai/public/artifacts/3dd6649c-e7bf-4f60-9771-28a79622d962 INMB INMB INMB
0 · Reply
ivanFlips
ivanFlips Apr. 27 at 9:49 AM
$BIIB what's next in pipeline milestones
0 · Reply
ClinicalTrialsDaily
ClinicalTrialsDaily Apr. 21 at 3:55 PM
$IONS Zilganersen's commercial success hinges primarily on execution beyond the trial rather than its strong clinical evidence. The real bottleneck isn't payer resistance—it's the diagnostic challenge. Patients frequently misdiagnosed as multiple sclerosis or atypical parkinsonism, getting an accurate diagnosis remains the biggest obstacle to reaching potential patients and driving revenue. $BIIB $SRPT $BMRN #AlexanderDisease Read more: www.clinicaltrialsdaily.com/zilganersen-aso-alexander-disease-pdufa/
0 · Reply
parcha
parcha Apr. 21 at 12:19 PM
Cramer's lightning round $BIIB Biogen: “I read the upgrade today by Wells Fargo, and it talked about a bunch of revenue streams, including Alzheimer’s, and it was very impressive. I actually said, ‘You know what? I got to reopen the file on Biogen.’ It looks pretty darn good.” https://www.cnbc.com/2026/04/20/cramers-lightning-round-buy-aes-corporation.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
parcha
parcha Apr. 21 at 10:49 AM
Lightning Round: Biogen looks pretty darn good, says Jim Cramer $BIIB https://www.cnbc.com/video/2026/04/20/lightning-round-biogen-looks-pretty-darn-good-says-jim-cramer.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
Latest News on BIIB
Biogen Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 17 hours ago

Biogen Earnings Call Transcript: Q1 2026

Biogen Lowers 2026 Earnings Outlook

Apr 29, 2026, 7:02 AM EDT - 18 hours ago

Biogen Lowers 2026 Earnings Outlook

Biogen cuts annual profit forecast on acquisition-related charges

Apr 29, 2026, 6:07 AM EDT - 19 hours ago

Biogen cuts annual profit forecast on acquisition-related charges

Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma

Apr 20, 2026, 9:02 AM EDT - 9 days ago

Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma

Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region

Apr 20, 2026, 7:30 AM EDT - 9 days ago

Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region

These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.

Apr 18, 2026, 9:00 AM EDT - 11 days ago

These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.

LLY

Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy's AntiClastic™ ASO Platform

Apr 7, 2026, 6:00 AM EDT - 22 days ago

Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy's AntiClastic™ ASO Platform

Why This Pharma Stock More Than Doubled Today

Mar 31, 2026, 9:41 AM EDT - 4 weeks ago

Why This Pharma Stock More Than Doubled Today

APLS

Biogen Transcript: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 4 weeks ago

Biogen Transcript: M&A announcement

Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases

Mar 31, 2026, 8:07 AM EDT - 4 weeks ago

Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases

APLS

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion

Mar 31, 2026, 7:44 AM EDT - 4 weeks ago

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion

APLS

Biogen to buy Apellis Pharmaceuticals for $5.6 billion

Mar 31, 2026, 7:05 AM EDT - 4 weeks ago

Biogen to buy Apellis Pharmaceuticals for $5.6 billion

APLS

Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology.

Mar 31, 2026, 6:59 AM EDT - 4 weeks ago

Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology.

APLS

Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

Mar 31, 2026, 6:59 AM EDT - 4 weeks ago

Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

APLS

Biogen Stock Pops After FDA Approves New High-Dose Spinraza For Spinal Muscular Atrophy

Mar 30, 2026, 1:40 PM EDT - 4 weeks ago

Biogen Stock Pops After FDA Approves New High-Dose Spinraza For Spinal Muscular Atrophy

US FDA approves higher-dose of Biogen's genetic disorder drug

Mar 30, 2026, 7:36 AM EDT - 4 weeks ago

US FDA approves higher-dose of Biogen's genetic disorder drug

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Mar 30, 2026, 7:30 AM EDT - 4 weeks ago

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

IONS

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

Mar 28, 2026, 3:00 PM EDT - 4 weeks ago

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

Mar 25, 2026, 8:00 AM EDT - 5 weeks ago

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

Mar 20, 2026, 12:05 PM EDT - 5 weeks ago

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

Mar 19, 2026, 7:30 AM EDT - 5 weeks ago

Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

Biogen Transcript: Stifel 2026 Virtual CNS Forum

Mar 18, 2026, 9:30 AM EDT - 6 weeks ago

Biogen Transcript: Stifel 2026 Virtual CNS Forum

Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

Mar 11, 2026, 8:00 AM EDT - 7 weeks ago

Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

Biogen Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 1:00 PM EDT - 7 weeks ago

Biogen Transcript: Leerink Global Healthcare Conference 2026

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

Mar 5, 2026, 7:30 AM EST - 7 weeks ago

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

IONS

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

Mar 4, 2026, 5:06 PM EST - 2 months ago

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

STOK

Biogen Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:10 AM EST - 2 months ago

Biogen Transcript: TD Cowen 46th Annual Health Care Conference

Biogen Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 13, 2026, 10:30 AM EST - 2 months ago

Biogen Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Biogen Announces Board Chair Transition

Feb 11, 2026, 5:00 PM EST - 2 months ago

Biogen Announces Board Chair Transition

Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings

Feb 9, 2026, 8:36 AM EST - 2 months ago

Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings

Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide

Feb 6, 2026, 8:59 AM EST - 2 months ago

Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide

Biogen Earnings Call Transcript: Q4 2025

Feb 6, 2026, 8:30 AM EST - 2 months ago

Biogen Earnings Call Transcript: Q4 2025

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.

Feb 6, 2026, 7:35 AM EST - 2 months ago

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.

Biogen forecasts annual profit above estimates as Leqembi sales pick up

Feb 6, 2026, 6:10 AM EST - 2 months ago

Biogen forecasts annual profit above estimates as Leqembi sales pick up

Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy

Feb 4, 2026, 7:30 AM EST - 3 months ago

Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy

Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

Jan 28, 2026, 7:30 AM EST - 3 months ago

Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review

Jan 25, 2026, 6:30 PM EST - 3 months ago

FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review

Biogen CEO Chris Viehbacher on 2026 drug pipeline outlook, rare disease strategy

Jan 13, 2026, 8:48 AM EST - 3 months ago

Biogen CEO Chris Viehbacher on 2026 drug pipeline outlook, rare disease strategy

Biogen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 4:30 PM EST - 3 months ago

Biogen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Jan 12, 2026, 11:05 AM EST - 3 months ago

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

Jan 11, 2026, 2:00 PM EST - 3 months ago

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

STOK

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China

Jan 5, 2026, 8:00 PM EST - 4 months ago

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China

The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS

Dec 22, 2025, 11:20 AM EST - 4 months ago

The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS

Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada

Dec 9, 2025, 7:00 AM EST - 5 months ago

Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada

“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

Dec 8, 2025, 6:30 PM EST - 5 months ago

“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Dec 5, 2025, 9:00 AM EST - 5 months ago

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

STOK

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Dec 5, 2025, 9:00 AM EST - 5 months ago

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Biogen Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 11:30 AM EST - 5 months ago

Biogen Transcript: Piper Sandler 37th Annual Healthcare Conference

New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

Dec 2, 2025, 4:40 PM EST - 5 months ago

New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

Biogen Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 12:55 PM EST - 5 months ago

Biogen Transcript: Evercore ISI 8th Annual HealthCONx Conference

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

Dec 1, 2025, 7:30 AM EST - 5 months ago

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

Dec 1, 2025, 7:30 AM EST - 5 months ago

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

STOK

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer's Disease in Japan

Nov 27, 2025, 7:30 PM EST - 5 months ago

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer's Disease in Japan

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Nov 25, 2025, 7:30 AM EST - 5 months ago

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data?

Nov 24, 2025, 11:17 AM EST - 5 months ago

Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data?

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

Nov 24, 2025, 7:30 AM EST - 5 months ago

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership

Nov 24, 2025, 7:30 AM EST - 5 months ago

Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership

Novo Nordisk Stock Falls After Ozempic Fails to Slow Alzheimer's in Trials. Biogen Jumps.

Nov 24, 2025, 7:25 AM EST - 5 months ago

Novo Nordisk Stock Falls After Ozempic Fails to Slow Alzheimer's in Trials. Biogen Jumps.

NVO

AI Stocks Are Taking a Beating. What to Buy Instead.

Nov 21, 2025, 1:13 PM EST - 5 months ago

AI Stocks Are Taking a Beating. What to Buy Instead.

AKAM AMZN EXPE LLY

Biogen Transcript: TD Cowen Immunology and Inflammation Summit

Nov 13, 2025, 4:30 PM EST - 5 months ago

Biogen Transcript: TD Cowen Immunology and Inflammation Summit

Biogen Transcript: Wedbush Rewind ASN 2025 Conference

Nov 10, 2025, 1:20 PM EST - 6 months ago

Biogen Transcript: Wedbush Rewind ASN 2025 Conference

Biogen Earnings Call Transcript: Q3 2025

Oct 30, 2025, 8:30 AM EDT - 6 months ago

Biogen Earnings Call Transcript: Q3 2025

Biogen Transcript: Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Sep 24, 2025, 11:20 AM EDT - 7 months ago

Biogen Transcript: Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Biogen Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 10:45 AM EDT - 8 months ago

Biogen Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Biogen Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 10:20 AM EDT - 8 months ago

Biogen Transcript: Cantor Global Healthcare Conference 2025

Biogen Earnings Call Transcript: Q2 2025

Jul 31, 2025, 8:30 AM EDT - 9 months ago

Biogen Earnings Call Transcript: Q2 2025

Biogen Transcript: AGM 2025

Jun 17, 2025, 9:00 AM EDT - 11 months ago

Biogen Transcript: AGM 2025

Biogen Transcript: Status Update

Jun 11, 2025, 10:00 AM EDT - 11 months ago

Biogen Transcript: Status Update

Biogen Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 10, 2025, 10:40 AM EDT - 11 months ago

Biogen Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Biogen Earnings Call Transcript: Q1 2025

May 1, 2025, 8:30 AM EDT - 1 year ago

Biogen Earnings Call Transcript: Q1 2025

Biogen Transcript: Stifel 2025 Virtual CNS Forum

Mar 18, 2025, 10:15 AM EDT - 1 year ago

Biogen Transcript: Stifel 2025 Virtual CNS Forum

Biogen Transcript: Leerink’s Global Healthcare Conference 2025

Mar 10, 2025, 11:20 AM EDT - 1 year ago

Biogen Transcript: Leerink’s Global Healthcare Conference 2025

Biogen Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 9:10 AM EST - 1 year ago

Biogen Transcript: TD Cowen 45th Annual Healthcare Conference

Biogen Earnings Call Transcript: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

Biogen Earnings Call Transcript: Q4 2024

Biogen Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 12:45 PM EST - 1 year ago

Biogen Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Biogen Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 3, 2024, 9:10 AM EST - 1 year ago

Biogen Transcript: 7th Annual Evercore ISI HealthCONx Conference

Biogen Earnings Call Transcript: Q3 2024

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Biogen Earnings Call Transcript: Q3 2024

Biogen Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 1:20 PM EDT - 1 year ago

Biogen Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Biogen Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 4, 2024, 10:00 AM EDT - 1 year ago

Biogen Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Biogen Earnings Call Transcript: Q2 2024

Aug 1, 2024, 8:30 AM EDT - 1 year ago

Biogen Earnings Call Transcript: Q2 2024

Biogen Transcript: AGM 2024

Jun 20, 2024, 9:00 AM EDT - 2 years ago

Biogen Transcript: AGM 2024

Biogen Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 12, 2024, 10:40 AM EDT - 2 years ago

Biogen Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Biogen Transcript: Jefferies Global Healthcare Conference

Jun 5, 2024, 12:30 PM EDT - 2 years ago

Biogen Transcript: Jefferies Global Healthcare Conference

Biogen Earnings Call Transcript: Q1 2024

Apr 24, 2024, 8:30 AM EDT - 2 years ago

Biogen Earnings Call Transcript: Q1 2024

Biogen Transcript: Stifel Virtual 2024 CNS Day

Mar 19, 2024, 10:00 AM EDT - 2 years ago

Biogen Transcript: Stifel Virtual 2024 CNS Day

Biogen Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 4, 2024, 11:10 AM EST - 2 years ago

Biogen Transcript: TD Cowen 44th Annual Health Care Conference 2024

Biogen Earnings Call Transcript: Q4 2023

Feb 13, 2024, 8:00 AM EST - 2 years ago

Biogen Earnings Call Transcript: Q4 2023

Biogen Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 8, 2024, 2:15 PM EST - 2 years ago

Biogen Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Biogen Transcript: The 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 9:10 AM EST - 2 years ago

Biogen Transcript: The 6th Annual Evercore ISI HealthCONx Conference

Biogen Earnings Call Transcript: Q3 2023

Nov 8, 2023, 8:00 AM EST - 2 years ago

Biogen Earnings Call Transcript: Q3 2023

Biogen Transcript: Financial Times: Decentralised Clinical Trials in Focus Conference

Sep 26, 2023, 10:00 AM EDT - 2 years ago

Biogen Transcript: Financial Times: Decentralised Clinical Trials in Focus Conference

Biogen Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 11, 2023, 10:40 AM EDT - 2 years ago

Biogen Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Biogen Transcript: M&A Announcement

Jul 28, 2023, 9:00 AM EDT - 2 years ago

Biogen Transcript: M&A Announcement

Biogen Earnings Call Transcript: Q2 2023

Jul 25, 2023, 8:00 AM EDT - 3 years ago

Biogen Earnings Call Transcript: Q2 2023

Biogen Earnings Call Transcript: Q1 2023

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Biogen Earnings Call Transcript: Q1 2023

Biogen Transcript: Stifel 2023 Virtual CNS Days

Mar 28, 2023, 9:15 AM EDT - 3 years ago

Biogen Transcript: Stifel 2023 Virtual CNS Days

Biogen Transcript: Cowen Health Care Conference

Mar 6, 2023, 9:50 AM EST - 3 years ago

Biogen Transcript: Cowen Health Care Conference

Biogen Earnings Call Transcript: Q4 2022

Feb 15, 2023, 8:00 AM EST - 3 years ago

Biogen Earnings Call Transcript: Q4 2022

Biogen Transcript: JPMorgan Healthcare Conference

Jan 9, 2023, 2:30 PM EST - 3 years ago

Biogen Transcript: JPMorgan Healthcare Conference

Biogen Transcript: Status Update

Dec 6, 2022, 8:30 AM EST - 3 years ago

Biogen Transcript: Status Update

Biogen Earnings Call Transcript: Q3 2022

Oct 25, 2022, 8:30 AM EDT - 3 years ago

Biogen Earnings Call Transcript: Q3 2022

Biogen Earnings Call Transcript: Q2 2022

Jul 20, 2022, 7:15 AM EDT - 4 years ago

Biogen Earnings Call Transcript: Q2 2022

Biogen Earnings Call Transcript: Q1 2022

May 3, 2022, 6:35 AM EDT - 4 years ago

Biogen Earnings Call Transcript: Q1 2022

Biogen Earnings Call Transcript: Q4 2021

Feb 3, 2022, 2:58 PM EST - 4 years ago

Biogen Earnings Call Transcript: Q4 2021

Biogen Transcript: Investor Update

Jan 13, 2022, 8:00 AM EST - 4 years ago

Biogen Transcript: Investor Update

Biogen Transcript: Investor Update

Nov 11, 2021, 8:00 AM EST - 4 years ago

Biogen Transcript: Investor Update

Biogen Earnings Call Transcript: Q3 2021

Oct 19, 2021, 8:00 PM EDT - 4 years ago

Biogen Earnings Call Transcript: Q3 2021

Biogen Transcript: Investor Day 2021

Sep 20, 2021, 8:00 PM EDT - 5 years ago

Biogen Transcript: Investor Day 2021

Biogen Earnings Call Transcript: Q2 2021

Jul 22, 2021, 3:19 PM EDT - 5 years ago

Biogen Earnings Call Transcript: Q2 2021

Biogen Transcript: Investor Update

Jun 8, 2021, 8:00 AM EDT - 5 years ago

Biogen Transcript: Investor Update

Biogen Transcript: AGM 2021

Jun 2, 2021, 8:00 AM EDT - 5 years ago

Biogen Transcript: AGM 2021

Biogen Earnings Call Transcript: Q1 2021

Apr 22, 2021, 9:13 AM EDT - 5 years ago

Biogen Earnings Call Transcript: Q1 2021

Biogen Transcript: Investor Update

Mar 13, 2021, 7:00 AM EST - 5 years ago

Biogen Transcript: Investor Update

Biogen Transcript: Investor Update

Mar 10, 2021, 7:00 AM EST - 5 years ago

Biogen Transcript: Investor Update

Biogen Transcript: Investor Update

Feb 23, 2021, 7:00 AM EST - 5 years ago

Biogen Transcript: Investor Update

Biogen Earnings Call Transcript: Q4 2020

Feb 3, 2021, 8:00 AM EST - 5 years ago

Biogen Earnings Call Transcript: Q4 2020

Biogen Earnings Call Transcript: Q3 2020

Oct 21, 2020, 8:00 AM EDT - 6 years ago

Biogen Earnings Call Transcript: Q3 2020

Biogen Earnings Call Transcript: Q2 2020

Jul 22, 2020, 8:00 AM EDT - 6 years ago

Biogen Earnings Call Transcript: Q2 2020

Biogen Earnings Call Transcript: Q1 2020

Apr 22, 2020, 8:00 AM EDT - 6 years ago

Biogen Earnings Call Transcript: Q1 2020

Biogen Earnings Call Transcript: Q4 2019

Jan 30, 2020, 8:00 AM EST - 6 years ago

Biogen Earnings Call Transcript: Q4 2019

Biogen Earnings Call Transcript: Q3 2019

Oct 22, 2019, 8:00 AM EDT - 7 years ago

Biogen Earnings Call Transcript: Q3 2019

Biogen Earnings Call Transcript: Q2 2019

Jul 23, 2019, 8:00 AM EDT - 7 years ago

Biogen Earnings Call Transcript: Q2 2019

Biogen Earnings Call Transcript: Q1 2019

Apr 24, 2019, 8:00 AM EDT - 7 years ago

Biogen Earnings Call Transcript: Q1 2019

Biogen Earnings Call Transcript: Q4 2018

Jan 29, 2019, 8:00 AM EST - 7 years ago

Biogen Earnings Call Transcript: Q4 2018

Biogen Earnings Call Transcript: Q3 2018

Oct 23, 2018, 8:00 AM EDT - 8 years ago

Biogen Earnings Call Transcript: Q3 2018

Biogen Earnings Call Transcript: Q2 2018

Jul 24, 2018, 8:00 AM EDT - 8 years ago

Biogen Earnings Call Transcript: Q2 2018

Biogen Earnings Call Transcript: Q1 2018

Apr 24, 2018, 8:00 AM EDT - 8 years ago

Biogen Earnings Call Transcript: Q1 2018

VolumeTactician
VolumeTactician Apr. 30 at 5:38 AM
$LEU $CAG $BIIB $BETA $AVPT Nuclear fuel/uranium theme, consumer staples stability, biotech pipelines, speculative tokens, and Microsoft-adjacent SaaS (AVPT) balance defense with growth.
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 30 at 3:55 AM
$BIIB Share Price: $194.59 Contract Selected: May 22, 2026 $195 Calls Buy Zone: $4.50 – $5.57 Target Zone: $8.02 – $9.80 Potential Upside: 68% ROI Time to Expiration: 22 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
RunnerSignals
RunnerSignals Apr. 29 at 8:10 PM
market warriors $TENB $HUM $CHGG $BIIB $SYRE reversed from red to strong green closes with 6–12% intraday swings and volume 1.2x–1.6x avg
0 · Reply
EarningsLens_ai
EarningsLens_ai Apr. 29 at 1:22 PM
$BIIB blew past estimates but the story underneath is more complicated. Cash flow nearly tripled, which sounds great until you see cost of revenue growing 3x faster than revenue and debt up 38% YoY to $6.29B. Q2 working capital reversal is the thing to watch.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Apr. 29 at 10:16 AM
$BIIB Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $2.17 up 31.52% YoY • Reported revenue of $2.48B up 1.93% YoY • Biogen updated full year 2026 Non-GAAP diluted EPS guidance to $14.25 to $15.25, reflecting an approximately $1.00 impact from acquired IPR&D charges, and expects total revenue to decline by a mid-single digit percentage.
0 · Reply
trichomy
trichomy Apr. 27 at 2:39 PM
$INMB $LEMB $BIIB Let's go InmuneBio!! https://claude.ai/public/artifacts/3dd6649c-e7bf-4f60-9771-28a79622d962 INMB INMB INMB
0 · Reply
ivanFlips
ivanFlips Apr. 27 at 9:49 AM
$BIIB what's next in pipeline milestones
0 · Reply
ClinicalTrialsDaily
ClinicalTrialsDaily Apr. 21 at 3:55 PM
$IONS Zilganersen's commercial success hinges primarily on execution beyond the trial rather than its strong clinical evidence. The real bottleneck isn't payer resistance—it's the diagnostic challenge. Patients frequently misdiagnosed as multiple sclerosis or atypical parkinsonism, getting an accurate diagnosis remains the biggest obstacle to reaching potential patients and driving revenue. $BIIB $SRPT $BMRN #AlexanderDisease Read more: www.clinicaltrialsdaily.com/zilganersen-aso-alexander-disease-pdufa/
0 · Reply
parcha
parcha Apr. 21 at 12:19 PM
Cramer's lightning round $BIIB Biogen: “I read the upgrade today by Wells Fargo, and it talked about a bunch of revenue streams, including Alzheimer’s, and it was very impressive. I actually said, ‘You know what? I got to reopen the file on Biogen.’ It looks pretty darn good.” https://www.cnbc.com/2026/04/20/cramers-lightning-round-buy-aes-corporation.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
parcha
parcha Apr. 21 at 10:49 AM
Lightning Round: Biogen looks pretty darn good, says Jim Cramer $BIIB https://www.cnbc.com/video/2026/04/20/lightning-round-biogen-looks-pretty-darn-good-says-jim-cramer.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
TangibleOne
TangibleOne Apr. 21 at 1:43 AM
$BIIB Long here and SKM (ticker) for the Anthropic pre IPO exposure!!!! 🤤
0 · Reply
EquityClock
EquityClock Apr. 20 at 7:19 PM
The optimal holding period for Biogen begins today and the break above resistance at the 20-day moving average is providing incremental evidence that the buying demand that is normally realized in the spring is clicking in. Shares of $BIIB have outperformed the market in 14 of the past 20 periods between April 18 and July 26. $IBB
0 · Reply
trichomy
trichomy Apr. 20 at 4:49 PM
$INMB $LEMB $BIIB $INMB
0 · Reply
LandonCapital
LandonCapital Apr. 20 at 12:26 PM
$BIIB https://landoncapital.net/making-a-big-splash-biogen-acquires-tj-biopharmas-felzartamab-for-850m/
0 · Reply
theflynews
theflynews Apr. 20 at 10:11 AM
Wells upgrades Biogen to Overweight on pipeline outside Alzheimer's - $BIIB - https://thefly.com/BIIB
0 · Reply
JFais
JFais Apr. 16 at 1:21 PM
$TVTX- had to rain on the parade didn't you @adamfeuerstein 😉 Good news $TVTX will build out the FSGS market and better treatments will follow (CCR2 blocker DMX-200 & complement inhibitors like $APLS $BIIB Empaveli in P3, BAFF APRIL a la atacicept & $VRTX poveticacicept, etc)
0 · Reply
trichomy
trichomy Apr. 16 at 12:21 PM
$INMB $LEMB $BIIB $INMB
0 · Reply
trichomy
trichomy Apr. 16 at 3:23 AM
$INMB Massive Paradigm Shift in Alzheimer's! The new Cochrane Review (CD016297) just dealt a devastating blow to the anti-amyloid hypothesis. 🚫 Gold-standard data from 42 trials shows that drugs like $LEMB and $BIIB clear plaque but fail to deliver meaningful cognitive benefits, while carrying serious safety risks like brain swelling (ARIA). 🤯 The market narrative is crumbling. Enter $INMB. Their lead asset, XPro™, targets neuroinflammation (soluble TNF), not amyloid. Cochrane's expert recommendation is clear: "Future research... should focus on other treatments." 💡 INmune Bio is the necessary evolution that Cochrane is inadvertently calling for. Structurally de-risked and perfectly positioned with XPro™ moving into pivotal trials with a biomarker-enriched design. Time to look beyond the failed amyloid funnel-vision. Check out my full strategic analysis in the graphic below! 🚀 #Alzheimers #Biotech #Investing #Neuroscience #TheNewNarrative https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016297/full?highlightAbstract=alzheimer%7Calzheimer%27s%7Calzheim
0 · Reply
Quantumup
Quantumup Apr. 15 at 11:19 AM
Mizuho🏁 $CLYM Outperform; $18 $RHHBY $BIIB VRTX GSK Mizuho said: We are initiating coverage of Climb Bio with an Outperform rating and $18 price target, as we see its lead assets budoprutug (anti-CD19 mAb) and CLYM116 (anti-APRIL mAb) as positioned to establish a compelling B-cell targeting pipeline with best-in-indication profiles in autoimmune nephropathies. Specifically, we believe additional updates for budoprutug in primary membranous nephropathy (pMN) in 2H26 and initial data for CLYM116 in healthy volunteers (HVs) in mid-2026 have the opportunity to provide data points that will validate potential to drive the deepest reductions in proteinuria within their competitive landscapes. As we exit 2026, budoprutug and CLYM116 could be positioned for registrational development across two blockbuster opportunities that we believe could support ~$600M in risk-adjusted WW sales by 2035.
0 · Reply
RunnerSignals
RunnerSignals Apr. 15 at 3:31 AM
upgrade flow shift $BIIB $ACM $ANET $F $BBY early accumulation on volume while consensus lags positioning https://stocksrunner.com/news/2026-04-14-top-stock-upgrades-today-in-the-buzz
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Apr. 14 at 3:11 PM
$BIIB
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 14 at 11:55 AM
$BIIB Share Price: $176.33 Contract Selected: May 08, 2026 $180 Calls Buy Zone: $3.82 – $4.73 Target Zone: $6.50 – $7.95 Potential Upside: 61% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply